Thursday, January 14, 2016 10:46:02 AM
Yes I sold 1/4 of my shares on 1/11 over $5 then sold more then another 1/2 of my share on 1/12 over $4 as we got more lawsuits stating the same thing and also because of the negative news about AVXL NOT BEING ABOUT TO TRADE On Certain Brokerage... That gave e a quick clue there will be more sell off...
Today went by Tom's T/A as he showed $3.30's being one of the support level and once I saw it wasn't going down as quickly I just went with my gut feeling to buy now... Low volume trading too help me to think no sell off just manipulation so buy now as they will gap this up like last time...
I bought in More Share today with the same amount as I like this company and the SCIENCE is Very Real with Substantial Backing by Best of the Best Scientist in the Field of what AVXL is accomplishing...
All Manipulation but I would recommend holding some share for the long run as it can be very Lucrative investment if everything goes to plan...
Below shows I bought in and going ALL IN AGAIN...
First Batch I bought in was for the 1/4 shares I sold at $3.33 and the second was when I saw it not going down I bought in all the Cash I had to buy in my account for $3.35 ish
AVXL
Today went by Tom's T/A as he showed $3.30's being one of the support level and once I saw it wasn't going down as quickly I just went with my gut feeling to buy now... Low volume trading too help me to think no sell off just manipulation so buy now as they will gap this up like last time...
I bought in More Share today with the same amount as I like this company and the SCIENCE is Very Real with Substantial Backing by Best of the Best Scientist in the Field of what AVXL is accomplishing...
All Manipulation but I would recommend holding some share for the long run as it can be very Lucrative investment if everything goes to plan...
Below shows I bought in and going ALL IN AGAIN...
First Batch I bought in was for the 1/4 shares I sold at $3.33 and the second was when I saw it not going down I bought in all the Cash I had to buy in my account for $3.35 ish
AVXL
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
